KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) Revenue (2016 - 2025)

Abbott Laboratories' Revenue history spans 17 years, with the latest figure at $11.5 billion for Q4 2025.

  • For Q4 2025, Revenue rose 4.42% year-over-year to $11.5 billion; the TTM value through Dec 2025 reached $44.3 billion, up 5.67%, while the annual FY2025 figure was $44.3 billion, 5.67% up from the prior year.
  • Revenue for Q4 2025 was $11.5 billion at Abbott Laboratories, up from $11.4 billion in the prior quarter.
  • Across five years, Revenue topped out at $11.9 billion in Q1 2022 and bottomed at $9.7 billion in Q1 2023.
  • The 5-year median for Revenue is $10.4 billion (2021), against an average of $10.7 billion.
  • The largest annual shift saw Revenue surged 39.51% in 2021 before it fell 18.06% in 2023.
  • A 5-year view of Revenue shows it stood at $11.5 billion in 2021, then fell by 12.01% to $10.1 billion in 2022, then rose by 1.49% to $10.2 billion in 2023, then increased by 7.16% to $11.0 billion in 2024, then rose by 4.42% to $11.5 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Revenue are $11.5 billion (Q4 2025), $11.4 billion (Q3 2025), and $11.1 billion (Q2 2025).